Last reviewed · How we verify

Tramadol HCI/acetaminophen

Janssen-Cilag Ltd.,Thailand · FDA-approved active Small molecule

Tramadol inhibits norepinephrine and serotonin reuptake while weakly binding opioid receptors, while acetaminophen inhibits prostaglandin synthesis to provide combined analgesic and antipyretic effects.

Tramadol inhibits norepinephrine and serotonin reuptake while weakly binding opioid receptors, while acetaminophen inhibits prostaglandin synthesis to provide combined analgesic and antipyretic effects. Used for Moderate to moderately severe pain.

At a glance

Generic nameTramadol HCI/acetaminophen
Also known asUltracet, ULTRACET immediate release tablet, YJAT sustained release tablet
SponsorJanssen-Cilag Ltd.,Thailand
Drug classOpioid analgesic combination
TargetMu opioid receptor, norepinephrine transporter, serotonin transporter, COX inhibition
ModalitySmall molecule
Therapeutic areaPain Management
PhaseFDA-approved

Mechanism of action

Tramadol is a synthetic opioid analgesic that works through dual mechanisms: it blocks the reuptake of norepinephrine and serotonin in the central nervous system and has weak mu-opioid receptor agonist activity. Acetaminophen (paracetamol) is a non-opioid analgesic and antipyretic that inhibits prostaglandin synthesis, primarily in the central nervous system. The combination provides enhanced pain relief through complementary mechanisms.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: